XML 61 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Summary Of Significant Accounting Policies - (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payer and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
March 31,
 20202019
Medicare25 %26 %
Blue Shield12 %13 %
United Healthcare10 %11 %
Medicare Advantage13 %10 %

 Accounts Receivable
 March 31, 2020December 31, 2019
 
United Healthcare22 %22 %
Blue Shield14 %15 %
Janssen (SIMPONI®)
 19 %

*Less than 10%.
Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payer and customer category (in thousands):
 
 Three Months Ended March 31,
 20202019
Revenue:
Healthcare insurers$6,062  $5,461  
Government2,245  2,432  
Client1,082  1,105  
Other(1)195  162  
Janssen (SIMPONI®)
—  100  
Total revenue$9,584  $9,260  
(1)Includes patient self-pay that is immaterial.
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 March 31, 2020December 31, 2019
 
Cash and cash equivalents$68,648  $72,084  
Restricted cash100  100  
$68,748  $72,184  
Schedule of Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 March 31, 2020December 31, 2019
 
Cash and cash equivalents$68,648  $72,084  
Restricted cash100  100  
$68,748  $72,184  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
 
 Three Months Ended March 31,
 20202019
Redeemable convertible preferred stock—  5,734,680  
Warrants to purchase redeemable convertible preferred stock—  224,493  
Warrants to purchase common stock436,581  934,789  
Common stock options1,630,014  662,365  
Total2,066,595  7,556,327